



**Universiteit  
Leiden**  
The Netherlands

## **Pathways to proteinuria**

Khalil, R.

### **Citation**


Khalil, R. (2024, June 4). *Pathways to proteinuria*. Retrieved from <https://hdl.handle.net/1887/3762004>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3762004>

**Note:** To cite this publication please use the final published version (if applicable).



# CHAPTER 7

## General discussion and future perspectives

Patients with proteinuria can suffer from a myriad of diseases that cause protein to pass the glomerular filtration barrier and being insufficiently reabsorbed by the proximal tubule apparatus. These diseases include those that are histopathologically characterized by scarring and fibrosis of glomeruli, such as both primary and secondary focal segmental glomerulosclerosis, and diabetic nephropathy. Other types of diseases leading to proteinuria could be classified as auto-immune mediated, such as lupus nephritis and membranous nephropathy. Moreover, many monogenetic diseases that cause proteinuria have been identified. Most of these display either a podocytopathy or a defect in tubular reabsorption. Although the underlying pathophysiological mechanisms differ between all of these diseases, they can share some elements in their respective pathways leading to proteinuria. As proteinuria is an independent risk factor for the progression of renal disease, cardiovascular morbidity, and overall mortality, treatments attenuating or relieving proteinuria are needed. Current treatment is mainly focused on the underlying disease and consists of reducing glomerular filtration pressure through inhibition of the renin-angiotensin-aldosterone system and, depending on whether an auto-immune or auto-inflammatory disease is involved, the addition of immunosuppressive drugs such as corticosteroids.

Elucidating the pathways leading to proteinuria is required to identify novel potential therapeutic targets for the treatment of proteinuria. Historically, the main constituents of the glomerular filtration barrier were identified through analysis of hereditary proteinuria syndromes, as also reviewed by Tryggvason *et al.*(16) For example, the slit diaphragm proteins of Nephtrin (*NPHS1*) and Podocin (*NPHS2*), glomerular basement membrane protein Laminin (*LAMB2*), and transcription factors that influence podocyte gene expression (*WT1* and *ACTN4*) were all identified by investigation of monogenetic proteinuric diseases.

As eloquently said by Iain Drummond: ‘unravelling the molecular pathogenesis of human disease presents many experimental challenges, not the least of which is that experiments on humans are generally frowned upon.(105)’ Although experimentation on animals is also increasingly frowned upon and must rightfully adhere to rigorous ethical standards, it is currently still an indispensable element of pathophysiological research. In this thesis, a combination of cell culture, experimental animal models, histopathological examination of human tissue, and a patient cohort investigation were all employed to investigate pathways leading to proteinuria.

## Nephropathic cystinosis

In chapter 2, an experimental zebrafish embryo model for the autosomal recessive disease of nephropathic cystinosis is introduced. Nephropathic cystinosis is a lysosomal storage disease where the *CTNS* gene is mutated, which leads to the accumulation of cystine in lysosomes. If left untreated, the disease is fatal.(106, 107) Currently, specific treatment is limited to cysteamine, which prevents further cystine accumulation but does not reverse the damage. Moreover, drug compliance is relatively low due to adverse effects of bad breath, skin odour, gastro-intestinal complaints such as nausea, vomiting, diarrhoea, and abdominal pain.(108-110) A *Ctns* knockout mouse has been developed, but this model lacks the glomerular changes also seen in nephropathic cystinosis.(111-113) The *ctns* *-/-* zebrafish mutant introduced in this study is presented as a promising model for the investigation of new therapeutic options and the pathophysiology of nephropathic cystinosis. The model displays a phenotype similar to that of the human disease, including cystine accumulation, increased glomerular permeability, and decreased proximal tubular reabsorption. They have higher mortality than wild-type animals. These last symptoms were preventable by treating mutant embryos with cysteamine. Renal and extrarenal manifestations of cystinosis have also been described in the adult model of this mutant.(114) The zebrafish cystinosis model has already been used to test novel treatment strategies for nephropathic cystinosis, such as luteolin, disulfiram, and bicalutamide-cysteamine.(115-118)

## Heparan sulphate glycosaminoglycans

Chapters 3 and 4 discuss the previously held paradigm that heparan sulphate glycosaminoglycans are essential to glomerular filtration barrier function. This hypothesis was formulated by Kanwar and Farquhar several decades ago and was based on the finding that enzymatic removal of HS-GAG resulted in the loss of GFB integrity.(7, 8) Also, HS-GAG expression has been found to be reduced in various proteinuric renal diseases.(22) However, based on the results presented in chapters 3 and 4, homozygous germline mutations in zebrafish and, respectively, heterozygous mutations in humans of HS backbone elongating enzymes are shown not to result in proteinuria, nor a renal phenotype. The role of HS-GAG has long been thought to provide the GFB its charge selectivity due to the negatively charged sulphate groups of heparan sulphate. In chapter 3, we show that a significant reduction in negatively charged sites in the glomerular basement membrane does not result in proteinuria. Results from other experimental animal models with HS-GAG deficiencies are in line with this notion.(23-25, 27, 119) In chapter 4, the effect of heterozygous germline mutations on the backbone elongating

enzymes of heparan sulphate glycosaminoglycans was investigated in patients with multiple osteochondromas. Multiple osteochondroma is an autosomal dominant disease caused by a mutation in either EXT1 or EXT2 leading to the formation of, as the name implies, multiple osteochondromas.(59, 60, 69) We investigated a cohort of multiple osteochondroma patients in a cross-sectional manner and found that they did not exhibit proteinuria or an altered endothelial glycocalyx. Also, we investigated a historic cohort of patients who had both an osteochondroma resection and kidney biopsy in their medical history. Upon re-examination of the slides, no specific glomerular morphological changes were observed. One patient did show a glomerular phenotype on electron microscopy similar to that of a described case of 'MO glomerulopathy' with focal fibril deposition. (56) The rare cases of MO glomerulopathy are hypothesized to be caused by local loss of heterozygosity.

In conclusion, the results from these studies support the growing body of evidence that loss of heparan sulphate glycosaminoglycans does not result in loss of glomerular filtration barrier integrity, despite resulting in loss of negatively charged sites.

### **Dynamin and GTPases**

One of the most promising potential therapeutic targets for the treatment of proteinuria is dynamin. Dynamin is known for its role clathrin-mediated endocytosis and synapse junction vesicle budding. Dynamin is a GTPase that forms a helical polymer around the neck of budding vesicles and causes membrane scission (120). In the kidney, it has been identified to be involved in the turnover of nephrin, direct interaction with actin and actin-regulatory proteins, and the endocytosis of albumin by podocytes. (11, 12, 14, 74) Its function depends on its oligomerization state and on whether it is cleaved by cathepsin L. (13, 14, 87, 121, 122) Schiffer *et al.* and Ono *et al.* demonstrated the potential of dynamin as a therapeutic target by treating several proteinuric animal models with Bis-T-23, which stimulates dynamin oligomerization. After administration, proteinuria decreased and the ultrastructure of podocyte foot processes was restored.(75, 76) In chapter 5, we show that glomerular dynamin mRNA expression increases before the onset of proteinuria and that both Dynamin and Cathepsin L protein expression is increased in proteinuric patients with various different underlying diseases. These results further support the suggested protective and dynamic role of dynamin in preventing the development of proteinuria through its interaction with the actin cytoskeleton and nephrin before the onset of proteinuria. As this mechanism also seems to play a role in proteinuric patients, this study further propagates the concept that dynamin and its regulation are potential therapeutic targets for the treatment of proteinuria.

Podocyte actin cytoskeletal regulation not only depends on dynamin, which is classed as a large GTPase, but also on the Rho-family of small GTPases like RhoA, Cdc42, and Rac1. They are involved in podocyte foot process motility and junctional and cytoskeletal interactions. Imbalances to the Rho GTPases are described to result in either hypo- or hypermobility of foot processes which both result in the progression of podocytopathy. (123) Rho GTPase signaling can be influenced by circulation factors such as soluble urokinase-type plasminogen activator receptor (suPAR), which activates Rac1. Inhibiting suPAR has been shown to inhibit podocyte injury *in vitro*. (124)

The results described in this thesis, combined with other literature on actin cytoskeleton regulation, expand the understanding that the GFB is not the static barrier it was once presumed to be, but rather an intricate apparatus that is dynamically regulated depending on local circumstances and circulating factors.

### **Transmembrane protein 14A**

In chapter 6, transmembrane protein 14A (TMEM14A) is reported as another important protein in the preservation of adequate GFB function and integrity. It was previously implied to be involved in suppressing Bax mediated apoptosis.(95) Other than that, TMEM14A is a relatively unknown protein. Here, we identified it to be involved in the development of proteinuria by examining the results of a microarray study in spontaneously proteinuric Dahl SS rats. There, it was found to be significantly downregulated compared to spontaneously hypertensive, non proteinuric rats. To establish whether TMEM14A plays a direct and essential role in the development of proteinuria, a zebrafish embryo knockdown model was utilized. Results from this study shows that knocking down TMEM14A translation results in loss of GFB integrity without affecting tubular reabsorption capacity. Next, we show that both mRNA and protein expression of TMEM14A is reduced before onset of proteinuria. This study also reveals that glomerular TMEM14A expression is increased in proteinuric kidney disease, except in diabetic nephropathy. This result corresponds with *in vitro* findings, where inducing podocyte damage also increases TMEM14A expression. A protective mechanism by TMEM14A is proposed with a potential action mechanism through inhibiting podocyte apoptosis. Further studies are required to assess whether this is indeed the case. It would be of particular interest to identify up- and downstream modulators of TMEM14A expression and function.

### **Zebrafish embryo model**

Zebrafish (*Danio rerio*) are freshwater fish originally from Southern Asia. They have become a widespread scientific model for the investigation of various pathophysiological

processes, including renal physiology. They are even part of the aquatic habitat on the International Space Station and are one of the few vertebrates to have lived a full life cycle in space.(125)

In chapters 2, 3, 5, and 6, an experimental zebrafish (*Danio rerio*) embryo model is used to assess whether knocking down mRNA translation of a single gene results in the development of proteinuria and whether tubular reabsorption mechanisms remain intact. Using this model presents several advantages compared to other experimental animal models. First, zebrafish embryos develop rapidly. Most major organs are formed within 40 hours post-fertilization. Due to their mostly transparent appearance, this development can be visualized relatively easily. Secondly, a single pair of adult zebrafish can lay over 200 eggs. Thus, in controlled conditions, it is possible to create high throughput models. The zebrafish embryo kidney consists of a pronephros with two nephrons that share a fused glomerulus in the midline of the body. Despite its simple structure compared to the more complex human metanephros, the zebrafish kidney shares many similar features with the kidneys of higher vertebrates and as such, is increasingly used as an experimental model for the study of cellular and molecular mechanisms of renal pathophysiology.(105, 126) Because of these characteristics, these animals are highly suited for investigating individual components of the pathways leading to proteinuria. (39, 40, 43, 82, 105, 126, 127)

In chapters 2 and 3, genetically mutated zebrafish were used as experimental models. In chapters 5 and 6, gene knockdown was effectuated by injecting zebrafish embryos with morpholino constructs. These constructs bind to mRNA and thus inhibit translation, leading to a functional knockdown of the targeted gene and its mRNA. In all these models, functional assays of glomerular filtration barrier integrity and tubular reabsorption were assessed by injecting a mixture of TRITC-labelled 3 kDa and FITC-labelled 70-kDa dextrans. As 3 kDa dextrans can freely pass the glomerular filtration barrier, they are reabsorbed in endosomes in the proximal tubule under physiological conditions. On the other hand, 70 kDa dextrans do not readily pass the GFB and as such, are only reabsorbed when GFB integrity is compromised. Thus, the presence of 3 kDa droplets was used to assess whether tubular reabsorption mechanism functions properly. The presence of 70 kDa was used to assess the loss of GFB integrity. This model was developed in these studies after adapting it from Hentschel *et al.* (40)

Other methods to assess GFB integrity in zebrafish embryos have also been developed by others. For example, a transgenic zebrafish expresses its main serum protein, vitamin D binding protein, bound with green fluorescent protein (EGFP). This model removes



the necessity to inject a dextran mixture but has no simultaneous assessment of tubular reabsorption function. With the introduction of this model, measuring the loss of fluorescence intensity in the zebrafish eye was also established as an indirect measurement of loss of GFB integrity. (45)

## Spontaneously proteinuric rat model

Laboratory rats (*Rattus norvegicus domestica*) are perhaps the most well-known experimental animal model, after mice. The first documented experiment on rats was performed in France back in 1856 and consisted of the examination of the effects of adrenalectomy.(128) Rats were also ahead of zebrafish regarding space travel, as they had joined Soviet space dogs Belka and Strelka aboard the Sputnik 5 in 1960. In this thesis, the spontaneously proteinuric Dahl salt-sensitive rat strain was compared with nonproteinuric spontaneously hypertensive rats in chapters 5 and 6. Although these two strains have similar blood pressure levels, the Dahl rats become progressively proteinuric as they age. The cause of early onset albuminuria in Dahl rats was previously found to be a polygenic trait.(79) In that study, genome-wide linkage, and quantitative trait loci (QTL) mapping analysis was performed. These QTLs were subsequently used to identify individual genes that are involved in the development of proteinuria. This was done by microarray analysis on purified Dahl and SHR glomeruli and comparing the differential regulation in time to the previously defined QTLs. Dynamin, which is discussed in chapter 5, was one of the cytoskeleton-related genes identified in this manner. TMEM14A was one of the most markedly downregulated genes in the comparison of relative expression prior to QTL correlation.

## Future perspectives

In conclusion, the work presented in this thesis adds to the knowledge of the pathways to proteinuria by both challenging the previously held tenet of a static filtration barrier and supporting the theories entailing a dynamically regulated interplay between the various layers of the glomerular filtration barrier in conjunction with the tubular reabsorption apparatus. As also reviewed by Comper *et al.*, the functionality of both the GFB and proximal tubular reabsorption seems to depend on whether proteinuric circumstances are present.(129) The expansion of comprehension of the pathophysiological mechanisms underlying pathways to proteinuria will be key to identifying new therapeutic targets. As described above, the novel zebrafish model of nephropathic cystinosis has already proven its worth for testing new therapeutic compounds whilst simultaneously offering new insights in the pathophysiology of cystinosis.

Regarding the role of negative charge and specifically, that of heparan sulphate glycosaminoglycans in the glomerular filtration barrier, it would be most interesting to investigate which proteins or circulating factors (next to the previously identified heparanase) influence its expression and degradation.(130, 131) Also, the changes in ligand binding ability of the glomerular glycocalyx might reveal more about the role of HS-GAG in maintaining GFB integrity.

Both large (dynamin) and small (Rho family) GTPases have already shown promise as therapeutic targets in preventing or even attenuating renal damage in proteinuric animal models. Compounds acting on these targets are yet to enter safety and efficacy testing for human trials but are an elegant example of translational medicine from a pathophysiological point of view. New potential targets, such as TMEM14A and its uncharted regulatory proteins, are being discovered at a high rate. As glomerular expression levels in human proteinuric kidneys in our TMEM14A experiments differed depending on etiology, it is conceivable that this particular pathway might not be of interest to all proteinuric diseases, but only a subset like diabetic nephropathy. It can be tentatively stated that the further identification of its protein-protein interactions including up- and downstream effects will reveal if this pathway to proteinuria is indeed a feasible therapeutic option.

The zebrafish experimental animal model has presented itself as an expedient model for both identifying and testing therapeutic targets. Further innovations in experimental animal models and especially in non-animal models such as organoids, will hopefully increase the rate of discovering potential targets and screening the effectiveness of therapeutic compounds. Thus, by further illuminating the pathways to proteinuria we hope to keep advancing the field towards targeted treatment of proteinuria for the benefit of our patients.

## References

1. Matsushita K, van d, V, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet*. 2010;375(9731):2073-81.
2. Group CW. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*. 2013.
3. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204-22.
4. Dane MJ, van den Berg BM, Lee DH, Boels MG, Tiemeier GL, Avramut MC, et al. A microscopic view on the renal endothelial glycocalyx. *American journal of physiology Renal physiology*. 2015;308(9):F956-66.
5. Dane MJ, Khairoun M, Lee DH, van den Berg BM, Eskens BJ, Boels MG, et al. Association of kidney function with changes in the endothelial surface layer. *Clinical journal of the American Society of Nephrology : CJASN*. 2014;9(4):698-704.
6. Rennke HG, Patel Y, Venkatachalam MA. Glomerular filtration of proteins: clearance of anionic, neutral, and cationic horseradish peroxidase in the rat. *Kidney Int*. 1978;13(4):278-88.
7. Kanwar YS, Farquhar MG. Presence of heparan sulfate in the glomerular basement membrane. *Proceedings of the National Academy of Sciences of the United States of America*. 1979;76(3):1303-7.
8. Kanwar YS, Linker A, Farquhar MG. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. *The Journal of cell biology*. 1980;86(2):688-93.
9. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. *Annual review of biochemistry*. 2002;71:435-71.
10. Miner JH. Glomerular basement membrane composition and the filtration barrier. *Pediatric nephrology*. 2011;26(9):1413-7.
11. Gu C, Chang J, Shchedrina VA, Pham VA, Hartwig JH, Suphamongmee W, et al. Regulation of dynamin oligomerization in cells: the role of dynamin-actin interactions and its GTPase activity. *Traffic*. 2014;15(8):819-38.
12. Gu C, Yaddanapudi S, Weins A, Osborn T, Reiser J, Pollak M, et al. Direct dynamin-actin interactions regulate the actin cytoskeleton. *EMBO J*. 2010;29(21):3593-606.
13. Sever S, Altintas MM, Nankoe SR, Moller CC, Ko D, Wei C, et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. *J Clin Invest*. 2007;117(8):2095-104.
14. Soda K, Balkin DM, Ferguson SM, Paradise S, Milosevic I, Giovedi S, et al. Role of dynamin, synaptojanin, and endophilin in podocyte foot processes. *J Clin Invest*. 2012;122(12):4401-11.
15. Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM. Disease-dependent mechanisms of albuminuria. *American journal of physiology Renal physiology*. 2008;295(6):F1589-600.
16. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. *The New England journal of medicine*. 2006;354(13):1387-401.
17. Koop K, Eikmans M, Wehland M, Baelde H, Ijpelaar D, Kreutz R, et al. Selective loss of podoplanin protein expression accompanies proteinuria and precedes alterations in podocyte morphology in a spontaneous proteinuric rat model. *Am J Pathol*. 2008;173(2):315-26.
18. Jungers P, Hannedouche T, Itakura Y, Albouze G, Descamps-Latscha B, Man NK. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. *Nephrol Dial Transplant*. 1995;10(8):1353-60.

19. Jeansson M, Haraldsson B. Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. *Am J Physiol Renal Physiol*. 2006;290(1):F111-F6.
20. Brenner BM, Hostetter TH, Humes HD. Molecular basis of proteinuria of glomerular origin. *N Engl J Med*. 1978;298(15):826-33.
21. Holmborn K, Habicher J, Kasza Z, Eriksson AS, Filipek-Gorniok B, Gopal S, et al. On the roles and regulation of chondroitin sulfate and heparan sulfate in zebrafish pharyngeal cartilage morphogenesis. *J Biol Chem*. 2012;287(40):33905-16.
22. van den Born J, van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Weening JJ, et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. *Kidney Int*. 1993;43(2):454-63.
23. Goldberg S, Harvey SJ, Cunningham J, Tryggvason K, Miner JH. Glomerular filtration is normal in the absence of both agrin and perlecan-heparan sulfate from the glomerular basement membrane. *Nephrol Dial Transplant*. 2009;24(7):2044-51.
24. Harvey SJ, Jarad G, Cunningham J, Rops AL, van d, V, Berden JH, et al. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. *Am J Pathol*. 2007;171(1):139-52.
25. Chen S, Wassenhove-McCarthy DJ, Yamaguchi Y, Holzman LB, van Kuppevelt TH, Jenniskens GJ, et al. Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria. *Kidney Int*. 2008;74(3):289-99.
26. Aoki S, Saito-Hakoda A, Yoshikawa T, Shimizu K, Kisu K, Suzuki S, et al. The reduction of heparan sulphate in the glomerular basement membrane does not augment urinary albumin excretion. *Nephrol Dial Transplant*. 2018;33(1):26-33.
27. Sugar T, Wassenhove-McCarthy DJ, Esko JD, van Kuppevelt TH, Holzman L, McCarthy KJ. Podocyte-specific deletion of NDST1, a key enzyme in the sulfation of heparan sulfate glycosaminoglycans, leads to abnormalities in podocyte organization in vivo. *Kidney Int*. 2014;85(2):307-18.
28. van Det NF, van den Born J, Tamsma JT, Verhagen NA, Berden JH, Bruijn JA, et al. Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells. *Kidney Int*. 1996;49(4):1079-89.
29. Singh A, Satchell SC, Neal CR, McKenzie EA, Tooke JE, Mathieson PW. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. *Journal of the American Society of Nephrology : JASN*. 2007;18(11):2885-93.
30. Lee JS, von der Hardt S, Rusch MA, Stringer SE, Stickney HL, Talbot WS, et al. Axon sorting in the optic tract requires HSPG synthesis by ext2 (dackel) and extl3 (boxer). *Neuron*. 2004;44(6):947-60.
31. Wiweger MI, Avramut CM, de Andrea CE, Prins FA, Koster AJ, Ravelli RB, et al. Cartilage ultrastructure in proteoglycan-deficient zebrafish mutants brings to light new candidate genes for human skeletal disorders. *J Pathol*. 2011;223(4):531-42.
32. Clement A, Wiweger M, von der HS, Rusch MA, Selleck SB, Chien CB, et al. Regulation of zebrafish skeletogenesis by ext2/dackel and papst1/pinscher. *PLoS Genet*. 2008;4(7):e1000136.
33. Wiweger MI, Zhao Z, van Merkesteyn RJ, Roehl HH, Hogendoorn PC. HSPG-deficient zebrafish uncovers dental aspect of multiple osteochondromas. *PloS one*. 2012;7(1):e29734.
34. van Eeden FJ, Granato M, Schach U, Brand M, Furutani-Seiki M, Haffter P, et al. Genetic analysis of fin formation in the zebrafish, *Danio rerio*. *Development*. 1996;123:255-62.
35. Faas FG, Avramut MC, van den Berg BM, Mommaas AM, Koster AJ, Ravelli RB. Virtual nanoscopy: generation of ultra-large high resolution electron microscopy maps. *The Journal of cell biology*. 2012;198(3):457-69.

36. de Andrea CE, Prins FA, Wiweger MI, Hogendoorn PC. Growth plate regulation and osteochondroma formation: insights from tracing proteoglycans in zebrafish models and human cartilage. *J Pathol.* 2011;224(2):160-8.
37. Hogendoorn PC, de Heer E, Weening JJ, Daha MR, Hoedemaeker PJ, Fleuren GJ. Glomerular capillary wall charge and antibody binding in passive Heymann nephritis. *The Journal of laboratory and clinical medicine.* 1988;111(2):150-7.
38. Gundersen HJ, Seefeldt T, Osterby R. Glomerular epithelial foot processes in normal man and rats. Distribution of true width and its intra- and inter-individual variation. *Cell Tissue Res.* 1980;205(1):147-55.
39. Ebarasi L, He L, Hultenby K, Takemoto M, Betsholtz C, Tryggvason K, et al. A reverse genetic screen in the zebrafish identifies *crb2b* as a regulator of the glomerular filtration barrier. *Developmental biology.* 2009;334(1):1-9.
40. Hentschel DM, Mengel M, Boehme L, Liebsch F, Albertin C, Bonventre JV, et al. Rapid screening of glomerular slit diaphragm integrity in larval zebrafish. *American journal of physiology Renal physiology.* 2007;293(5):F1746-50.
41. Schurer JW, Hoedemaeker J, Molenaar I. Polyethyleneimine as tracer particle for (immuno) electron microscopy. *J Histochem Cytochem.* 1977;25(5):384-7.
42. Rosenzweig LJ, Kanwar YS. Removal of sulfated (heparan sulfate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125I-bovine serum albumin. *Lab Invest.* 1982;47(2):177-84.
43. Hanke N, Staggs L, Schroder P, Litteral J, Fleig S, Kaufeld J, et al. "Zebrafishing" for novel genes relevant to the glomerular filtration barrier. *BioMed research international.* 2013;2013:658270.
44. Laurent TC, Sundelof LO, Wik KO, Warmegard B. Diffusion of dextran in concentrated solutions. *Eur J Biochem.* 1976;68(1):95-102.
45. Hanke N, King BL, Vaske B, Haller H, Schiffer M. A Fluorescence-Based Assay for Proteinuria Screening in Larval Zebrafish (*Danio rerio*). *Zebrafish.* 2015;12(5):372-6.
46. Rider SA, Bruton FA, Collins RG, Conway BR, Mullins JJ. The Efficacy of Puromycin and Adriamycin for Induction of Glomerular Failure in Larval Zebrafish Validated by an Assay of Glomerular Permeability Dynamics. *Zebrafish.* 2018;15(3):234-42.
47. Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. *J Pathol.* 2012;226(4):562-74.
48. Miner JH. Glomerular filtration: the charge debate charges ahead. *Kidney Int.* 2008;74(3):259-61.
49. Nayak BR, Spiro RG. Localization and structure of the asparagine-linked oligosaccharides of type IV collagen from glomerular basement membrane and lens capsule. *J Biol Chem.* 1991;266(21):13978-87.
50. Bernard MA, Hogue DA, Cole WG, Sanford T, Snuggs MB, Montufar-Solis D, et al. Cytoskeletal abnormalities in chondrocytes with EXT1 and EXT2 mutations. *J Bone Miner Res.* 2000;15(3):442-50.
51. Lin X, Wei G, Shi Z, Dryer L, Esko JD, Wells DE, et al. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. *Developmental biology.* 2000;224(2):299-311.
52. Xu D, Esko JD. Demystifying heparan sulfate-protein interactions. *Annual review of biochemistry.* 2014;83:129-57.
53. Garsen M, Rops AL, Rabelink TJ, Berden JH, van der Vlag J. The role of heparanase and the endothelial glycocalyx in the development of proteinuria. *Nephrol Dial Transplant.* 2014;29(1):49-55.
54. Harvey SJ, Jarad G, Cunningham J, Rops AL, van der Vlag J, Berden JH, et al. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. *Am J Pathol.* 2007;171(1):139-52.

55. Khalil R, Lalai RA, Wiweger MI, Avramut CM, Koster AJ, Spaink HP, et al. Glomerular permeability is not affected by heparan sulfate glycosaminoglycan deficiency in zebrafish embryos. *American journal of physiology Renal physiology*. 2019;317(5):F1211-F6.
56. Roberts IS, Gleadle JM. Familial nephropathy and multiple exostoses with exostosin-1 (EXT1) gene mutation. *Journal of the American Society of Nephrology : JASN*. 2008;19(3):450-3.
57. Colvin RB, Chang A. *Diagnostic Pathology: Kidney Diseases: Elsevier Health Sciences*; 2015.
58. Wuyts W, Van Hul W. Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2 genes. *Human mutation*. 2000;15(3):220-7.
59. Bovee JV. Multiple osteochondromas. *Orphanet journal of rare diseases*. 2008;3:3.
60. Bovee JV, Hogendoorn PC. Multiple osteochondromas. In: Fletcher CDM, Unni KK, Mertens F, editors. *World Health Organization classification of tumours : pathology and genetics tumours of soft tissue and bone*. Lyon: IARC Publications; 2002. p. 360–2.
61. Le Merrer M, Legeai-Mallet L, Jeannin PM, Horsthemke B, Schinzel A, Plauchu H, et al. A gene for hereditary multiple exostoses maps to chromosome 19p. *Human molecular genetics*. 1994;3(5):717-22.
62. Hameetman L, Bovee JV, Taminiu AH, Kroon HM, Hogendoorn PC. Multiple osteochondromas: clinicopathological and genetic spectrum and suggestions for clinical management. *Hereditary cancer in clinical practice*. 2004;2(4):161-73.
63. Anower EKMF, Matsumoto K, Habuchi H, Morita H, Yokochi T, Shimizu K, et al. Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application. *Glycobiology*. 2013;23(7):865-76.
64. Hecht JT, Hall CR, Snuggs M, Hayes E, Haynes R, Cole WG. Heparan sulfate abnormalities in exostosis growth plates. *Bone*. 2002;31(1):199-204.
65. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. *Pflügers Archiv : European journal of physiology*. 2007;454(3):345-59.
66. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. *Circulation*. 2007;115(10):1285-95.
67. Stam F, van Guldener C, Becker A, Dekker JM, Heine RJ, Bouter LM, et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. *Journal of the American Society of Nephrology : JASN*. 2006;17(2):537-45.
68. Lee DH, Dane MJ, van den Berg BM, Boels MG, van Teeffelen JW, de Mutsert R, et al. Deeper penetration of erythrocytes into the endothelial glycocalyx is associated with impaired microvascular perfusion. *PloS one*. 2014;9(5):e96477.
69. Bovee JV, Cleton-Jansen AM, Wuyts W, Caethoven G, Taminiu AH, Bakker E, et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. *American journal of human genetics*. 1999;65(3):689-98.
70. Reijnders CM, Waaijer CJ, Hamilton A, Buddingh EP, Dijkstra SP, Ham J, et al. No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas. *Am J Pathol*. 2010;177(4):1946-57.
71. Wiweger MI, de Andrea CE, Scheepstra KW, Zhao Z, Hogendoorn PC. Possible effects of EXT2 on mesenchymal differentiation--lessons from the zebrafish. *Orphanet J Rare Dis*. 2014;9:35.
72. Eickhoff MK, Winther SA, Hansen TW, Diaz LJ, Persson F, Rossing P, et al. Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions. *PloS one*. 2020;15(12):e0243737.
73. Raghavan V, Rbaibi Y, Pastor-Soler NM, Carattino MD, Weisz OA. Shear stress-dependent regulation of apical endocytosis in renal proximal tubule cells mediated by primary cilia. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(23):8506-11.

74. Dobrinskikh E, Okamura K, Kopp JB, Doctor RB, Blaine J. Human podocytes perform polarized, caveolae-dependent albumin endocytosis. *American journal of physiology Renal physiology*. 2014;306(9):F941-51.
75. Schiffer M, Teng B, Gu C, Shchedrina VA, Kasaikina M, Pham VA, et al. Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models. *Nature medicine*. 2015;21(6):601-9.
76. Ono S, Kume S, Yasuda-Yamahara M, Yamahara K, Takeda N, Chin-Kanasaki M, et al. O-linked beta-N-acetylglucosamine modification of proteins is essential for foot process maturation and survival in podocytes. *Nephrol Dial Transplant*. 2017;32(9):1477-87.
77. Wang J, Duncan D, Shi Z, Zhang B. WEB-based GENE SeT AnaLysis Toolkit (WebGestalt): update 2013. *Nucleic acids research*. 2013;41(Web Server issue):W77-83.
78. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic acids research*. 2000;28(1):27-30.
79. Mehr AP, Siegel AK, Kossmehl P, Schulz A, Plehm R, de Bruijn JA, et al. Early onset albuminuria in Dahl rats is a polygenetic trait that is independent from salt loading. *Physiological genomics*. 2003;14(3):209-16.
80. Baelde JJ, Bergijk EC, Hoedemaeker PJ, de Heer E, Bruijn JA. Optimal method for RNA extraction from mouse glomeruli. *Nephrology Dialysis Transplant*. 1995;9:304-8.
81. Westerfield M. *The zebrafish book : a guide for the laboratory use of zebrafish (Danio rerio)*. [Eugene, OR]: Institute of Neuroscience, University of Oregon; 2007.
82. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. *Dev Dyn*. 1995;203(3):253-310.
83. FEDERA. *Human Tissue and Medical Research: Code of conduct for responsible use*. 2011.
84. Koop K, Eikmans M, Baelde HJ, Kawachi H, De Heer E, Paul LC, et al. Expression of podocyte-associated molecules in acquired human kidney diseases. *Journal of the American Society of Nephrology : JASN*. 2003;14(8):2063-71.
85. Chugh SS, Clement LC, Mace C. New insights into human minimal change disease: lessons from animal models. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2012;59(2):284-92.
86. Davidson A. What is damaging the kidney in lupus nephritis? *Nature reviews Rheumatology*. 2016;12(3):143-53.
87. Sampogna RV, Al-Awqati Q. Taking a bite: endocytosis in the maintenance of the slit diaphragm. *J Clin Invest*. 2012;122(12):4330-3.
88. Qin XS, Tsukaguchi H, Shono A, Yamamoto A, Kurihara H, Doi T. Phosphorylation of nephrin triggers its internalization by raft-mediated endocytosis. *Journal of the American Society of Nephrology : JASN*. 2009;20(12):2534-45.
89. Waters AM, Wu MY, Huang YW, Liu GY, Holmyard D, Onay T, et al. Notch promotes dynamin-dependent endocytosis of nephrin. *Journal of the American Society of Nephrology : JASN*. 2012;23(1):27-35.
90. Garrett MR, Dene H, Rapp JP. Time-course genetic analysis of albuminuria in Dahl salt-sensitive rats on low-salt diet. *Journal of the American Society of Nephrology : JASN*. 2003;14(5):1175-87.
91. Garrett MR, Joe B, Yerga-Woolwine S. Genetic linkage of urinary albumin excretion in Dahl salt-sensitive rats: influence of dietary salt and confirmation using congenic strains. *Physiological genomics*. 2006;25(1):39-49.
92. Siegel AK, Kossmehl P, Planert M, Schulz A, Wehland M, Stoll M, et al. Genetic linkage of albuminuria and renal injury in Dahl salt-sensitive rats on a high-salt diet: comparison with spontaneously hypertensive rats. *Physiological genomics*. 2004;18(2):218-25.
93. Khalil R, Koop K, Kreutz R, Spaink HP, Hogendoorn PC, Bruijn JA, et al. Increased dynamin expression precedes proteinuria in glomerular disease. *J Pathol*. 2019;247(2):177-85.

94. Klammt C, Maslennikov I, Bayrhuber M, Eichmann C, Vajpai N, Chiu EJ, et al. Facile backbone structure determination of human membrane proteins by NMR spectroscopy. *Nature methods*. 2012;9(8):834-9.
95. Woo IS, Jin H, Kang ES, Kim HJ, Lee JH, Chang KC, et al. TMEM14A inhibits N-(4-hydroxyphenyl)retinamide-induced apoptosis through the stabilization of mitochondrial membrane potential. *Cancer Lett*. 2011;309(2):190-8.
96. Lee SH, Yoo TH, Nam BY, Kim DK, Li JJ, Jung DS, et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. *American journal of physiology Renal physiology*. 2009;297(5):F1381-90.
97. Zhou LL, Cao W, Xie C, Tian J, Zhou Z, Zhou Q, et al. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. *Kidney Int*. 2012;82(7):759-70.
98. Zhou LL, Hou FF, Wang GB, Yang F, Xie D, Wang YP, et al. Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms. *Kidney Int*. 2009;76(11):1148-60.
99. Cardoso VG, Goncalves GL, Costa-Pessoa JM, Thieme K, Lins BB, Casare FAM, et al. Angiotensin II-induced podocyte apoptosis is mediated by endoplasmic reticulum stress/PKC-delta/p38 MAPK pathway activation and through increased Na(+)/H(+) exchanger isoform 1 activity. *BMC Nephrol*. 2018;19(1):179.
100. Tao Y, Yazdizadeh Shotorbani P, Inman D, Das-Earl P, Ma R. Store-operated Ca(2+) entry inhibition ameliorates high glucose and Ang induced podocyte apoptosis and mitochondria damage. *American journal of physiology Renal physiology*. 2023.
101. Yamamoto K, Okabe M, Tanaka K, Yokoo T, Pastan I, Araoka T, et al. Podocytes are lost from glomeruli before completing apoptosis. *American journal of physiology Renal physiology*. 2022;323(5):F515-F26.
102. Elmonem MA, Khalil R, Khodaparast L, Khodaparast L, Arcolino FO, Morgan J, et al. Cystinosis (ctns) zebrafish mutant shows pronephric glomerular and tubular dysfunction. *Sci Rep*. 2017;7:42583.
103. Nagata M. Podocyte injury and its consequences. *Kidney Int*. 2016;89(6):1221-30.
104. Kok FO, Shin M, Ni CW, Gupta A, Grosse AS, van Impel A, et al. Reverse genetic screening reveals poor correlation between morpholino-induced and mutant phenotypes in zebrafish. *Dev Cell*. 2015;32(1):97-108.
105. Drummond IA. Kidney development and disease in the zebrafish. *Journal of the American Society of Nephrology : JASN*. 2005;16(2):299-304.
106. Gahl WA, Thoene JG, Schneider JA. Cystinosis. *The New England journal of medicine*. 2002;347(2):111-21.
107. Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, et al. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. *Nat Genet*. 1998;18(4):319-24.
108. Dohil R, Fidler M, Barshop BA, Gangoiti J, Deutsch R, Martin M, et al. Understanding intestinal cysteamine bitartrate absorption. *J Pediatr*. 2006;148(6):764-9.
109. Besouw M, Blom H, Tangerman A, de Graaf-Hess A, Levtchenko E. The origin of halitosis in cystinotic patients due to cysteamine treatment. *Molecular genetics and metabolism*. 2007;91(3):228-33.
110. Ariceta G, Lara E, Camacho JA, Oppenheimer F, Vara J, Santos F, et al. Cysteamine (Cystagon(R)) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults. *Nephrol Dial Transplant*. 2015;30(3):475-80.
111. Cherqui S, Sevin C, Hamard G, Kalatzis V, Sich M, Pequignot MO, et al. Intralysosomal Cystine Accumulation in Mice Lacking Cystinosis, the Protein Defective in Cystinosis. *Molecular and Cellular Biology*. 2002;22(21):7622-32.



112. Gaide Chevronnay HP, Janssens V, Van Der Smissen P, N’Kuli F, Nevo N, Guiot Y, et al. Time course of pathogenic and adaptation mechanisms in cystinotic mouse kidneys. *Journal of the American Society of Nephrology : JASN*. 2014;25(6):1256-69.
113. Nevo N, Chol M, Bailleux A, Kalatzis V, Morisset L, Devuyst O, et al. Renal phenotype of the cystinosis mouse model is dependent upon genetic background. *Nephrol Dial Transplant*. 2010;25(4):1059-66.
114. Berlingerio SP, He J, De Groef L, Taeter H, Norton T, Baatsen P, et al. Renal and Extra Renal Manifestations in Adult Zebrafish Model of Cystinosis. *Int J Mol Sci*. 2021;22(17).
115. Taranta A, Elmonem MA, Bellomo F, De Leo E, Boenzi S, Janssen MJ, et al. Benefits and Toxicity of Disulfiram in Preclinical Models of Nephropathic Cystinosis. *Cells*. 2021;10(12).
116. Jamalpoor A, van Gelder CA, Yousef Yengej FA, Zaal EA, Berlingerio SP, Veys KR, et al. Cysteamine-bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis. *EMBO molecular medicine*. 2021;13(7):e13067.
117. Jamalpoor A, Othman A, Levchenko EN, Masereeuw R, Janssen MJ. Molecular Mechanisms and Treatment Options of Nephropathic Cystinosis. *Trends Mol Med*. 2021;27(7):673-86.
118. De Leo E, Elmonem MA, Berlingerio SP, Berquez M, Festa BP, Raso R, et al. Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis. *Journal of the American Society of Nephrology : JASN*. 2020;31(7):1522-37.
119. Wijnhoven TJ, Lensen JF, Wismans RG, Lamrani M, Monnens LA, Wevers RA, et al. In vivo degradation of heparan sulfates in the glomerular basement membrane does not result in proteinuria. *J Am Soc Nephrol*. 2007;18(3):823-32.
120. Praefcke GJ, McMahon HT. The dynamin superfamily: universal membrane tubulation and fission molecules? *Nat Rev Mol Cell Biol*. 2004;5(2):133-47.
121. Reiser J, Oh J, Shirato I, Asanuma K, Hug A, Mundel TM, et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. *J Biol Chem*. 2004;279(33):34827-32.
122. Yaddanapudi S, Altintas MM, Kistler AD, Fernandez I, Moller CC, Wei C, et al. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. *J Clin Invest*. 2011;121(10):3965-80.
123. Kistler AD, Altintas MM, Reiser J. Podocyte GTPases regulate kidney filter dynamics. *Kidney Int*. 2012;81(11):1053-5.
124. Rashmi P, Sigdel TK, Rychkov D, Damm I, Da Silva AA, Vincenti F, et al. Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors. *Ann Transl Med*. 2023;11(9):315.
125. Ijiri K. Life-cycle experiments of medaka fish aboard the international space station. *Adv Space Biol Med*. 2003;9:201-16.
126. Drummond IA, Majumdar A, Hentschel H, Elger M, Solnica-Krezel L, Schier AF, et al. Early development of the zebrafish pronephros and analysis of mutations affecting pronephric function. *Development*. 1998;125(23):4655-67.
127. Ebarasi L, Oddsson A, Hultenby K, Betsholtz C, Tryggvason K. Zebrafish: a model system for the study of vertebrate renal development, function, and pathophysiology. *Current opinion in nephrology and hypertension*. 2011;20(4):416-24.
128. Modlinska K, Pisula W. The Norway rat, from an obnoxious pest to a laboratory pet. *Elife*. 2020;9.
129. Comper WD, Vuchkova J, McCarthy KJ. New insights into proteinuria/albuminuria. *Front Physiol*. 2022;13:991756.
130. Garsen M, Rops AL, Rabelink TJ, Berden JH, van d, V. The role of heparanase and the endothelial glycocalyx in the development of proteinuria. *Nephrol Dial Transplant*. 2014;29(1):49-55.
131. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, et al. Heparanase is essential for the development of diabetic nephropathy in mice. *Diabetes*. 2012;61(1):208-16.